Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126070 · ClinicalTrials.gov registry record · Phase 2
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
A Phase 2 study of Prostate Adenocarcinoma and Hormone Sensitive Prostate Cancer, sponsored by Xiao X. Wei, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT04126070 is a Phase 2 study of Prostate Adenocarcinoma and Hormone Sensitive Prostate Cancer that is active but no longer recruiting, run by Xiao X. Wei, MD. The registered enrollment target is 60 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (72% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04126070, a Phase 2 study of Prostate Adenocarcinoma and Hormone Sensitive Prostate Cancer, is active but no longer recruiting, sponsored by Xiao X. Wei, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: * Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon). * Docetaxel * Nivolumab
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Nivolumab
- DRUG Androgen Deprivation Therapy
Study Locations (6)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- University of California, San Diego - La Jolla
Florida
- H. Lee Moffitt Cancer Center - Tampa
Maryland
- The Johns Hopkins University School of Medicine - Baltimore
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04126070
The ClinicalTrials.gov registry entry for NCT04126070 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (72% lower). The listed sponsor is Xiao X. Wei, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT04126070 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04126070 about?
NCT04126070 is a clinical study titled "Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors". This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: * Androgen deprivation therapy (ADT) with a drug of your physician's ...
What is the current status of trial NCT04126070?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-05-11. Estimated completion is 2026-06-30.
What conditions does trial NCT04126070 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer, Metastasis Prostate Adenocarcinoma.
What interventions are being tested in trial NCT04126070?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (DRUG), Androgen Deprivation Therapy (DRUG).
Who is sponsoring clinical trial NCT04126070?
This trial is sponsored by Xiao X. Wei, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04126070 being conducted?
This trial has 6 study locations across California, Florida, Maryland, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Prostate Adenocarcinoma
All registered trials for this condition
Hormone Sensitive Prostate Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.